Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842090 | 0.90 | GPR119 (0.53) | ACHEGPR119ALDH1A1SLC2A1KDM4E | |
| SCHEMBL4841732 | 0.88 | ACHE (0.55) | ACHEMEN1KMT2APOLBPTGIR | |
| SCHEMBL6376440 | 0.88 | ACHE (0.56) | ACHEALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6372221 | 0.87 | ACHE (0.54) | ACHEMEN1KMT2APOLBPTGIR | |
| SCHEMBL4840176 | 0.87 | ACHE (0.53) | ACHEALDH1A1KDM4EBACE1MEN1 | |
| Hydrochloric Acid SCHEMBL4841747 | 0.84 | ACHE (0.51) | ACHEALDH1A1KDM4EBACE1MEN1 | |
| Hydrochloric Acid SCHEMBL6376437 | 0.84 | ACHE (0.51) | ACHEALDH1A1KDM4EBACE1MEN1 | |
| Hydrochloric Acid SCHEMBL6371484 | 0.84 | ACHE (0.55) | ACHEKDM4EBACE1MEN1KMT2A | |
| SCHEMBL5868024 | 0.83 | KDM4E (0.58) | ACHEGPR119ALDH1A1SLC2A1KDM4E | |
| Trifluoroacetic Acid SCHEMBL4837060 | 0.82 | ACHE (0.49) | ACHEALDH1A1BACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1192132-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | ACHE 3190/4885GPR119 4587/4885ALDH1A1 2408/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | ACHE 1271/4885GPR119 3347/4885ALDH1A1 2527/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ACHE 2174/4885GPR119 2989/4885ALDH1A1 2261/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ACHE 2174/4885GPR119 2989/4885ALDH1A1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.